Regenerations Ahead

Biostage is a clinical-stage biotechnology company that uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed by a surgeon due to cancer, trauma or birth defects.

The cells on the scaffold stimulate the body’s natural regeneration process (much as your body heals any wound, such as a cut on your arm) and the scaffold guides the newly-formed tissue into the shape of the patient’s own esophagus.

Once the regeneration is complete, typically after about 3 months, the scaffold is removed via the mouth. No surgical incision is needed to remove the scaffold.

The Biostage Esophageal Implant regenerates the patient’s own esophagus.

  • It is not a transplant of someone else’s organ.
  • It is not a piece of your bowel or stomach in your chest, which are the current treatments for esophageal cancer.
  • It is not a transplant of a pig’s organ.
  • It is not piece of plastic mesh left inside your body.

It is your own organ, regenerated. There aren’t even any stitches (sutures) left behind.

To see how this is done, please click here.

Doctors at world class hospitals have described the Biostage Esophageal Implant as “revolutionary”, “a breakthrough” and that “would have considerable clinical use”. To hear doctors talk about the Biostage Esophageal Implant please click here.

The world’s first regeneration of an esophagus in a human cancer patient was performed using the Biostage Esophageal Implant at Mayo Clinic. The paper was published in August 2021. Please click here to read the paper.

We have also completed extensive large-animal research to lay the scientific foundation for using the Biostage Esophageal Implant to repair birth defects in babies who are born without a complete esophagus.

On the basis of this successful implant, and our extensive large animal research, the FDA has approved a clinical trial for the Biostage Esophageal Implant.

If you would like further information about this clinical trial, please email our Chief Scientific Officer, Dr. William Fodor

If you are an accredited investor (which for many people means an income of more than $200,000 a year or investable assets outside the home of more than $1,000,000) and would like to find out more about how to invest in Biostage to help us fund the clinical trial and also to research further application of the technology in conditions like colon cancer and bronchus cancer please contact us here.